Skip to main content
. 2020 Jan 7;11(1):31–45. doi: 10.18632/oncotarget.27414

Figure 1. Production of specific anti-HER3 rat mAb.

Figure 1

(A) Scheme for the sandwich ELISA (sELISA) with soluble HER3-GFP proteins for the selection of anti-HER3 mAbs. (B) An example of first screening of anti-HER3 mAbs using sELISA. (C) Second and third FCM screenings of anti-HER3 mAbs using HEK293 transfectants expressing GFP-fused HER family proteins. (D) Representative FCM histograms showing the reactivity of anti-HER3 mAb (Ab4) with human cancer cell lines.